Novo Nordisk plans to file a label expansion for Rybelsus (oral semaglutide) as an adjunct treatment for the prevention of major adverse cardiovascular events (MACE) in patients with type 2 ...

The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic, Wegovy, Rybelsus, and Saxenda. The main compound that Ozempic, Wegovy, and Rybelsus ...

Rybelsus is a glucagon-like peptide-1 (GLP-1) agonist available as a tablet. It is used to treat type 2 diabetes. Metformin ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...

Novo Nordisk plans to seek regulatory approval for Rybelsus label expansion by late 2024 or early 2025. On Monday, Novo Nordisk A/S NVO released the headline results from the SOUL Phase 3 ...

Please note that NVO already markets oral semaglutide in the United States under the brand name Rybelsus. It is administered once daily and comes in three approved doses, 3 mg, 7 mg and 14 mg.

Rybelsus is available as an oral tablet. Take Rybelsus with no more than 4 ounces (oz.) of water about 30 minutes before your ...